Noplag™Tablet: Each film-coated tablet contains Ticagrelor BP 90 mg.
Noplag™ is a preparation of Ticagrelor. Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent.
Pregnancy Category C: There are no adequate and well-controlled studies of Ticagrelor use in pregnant women. In animal studies, Ticagrelor caused structural abnormalities at maternal doses about 5 to 7 times the maximum recommended human dose (MRHD) based on body surface area. Ticagrelor should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Ticagrelor or its active metabolites are excreted in human milk. Ticagrelor is excreted in rat milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Ticagrelor, a decision should be made whether to discontinue nursing or to discontinue Ticagrelor.
Dyspnea was reported more frequently with Ticagrelor than with control agents in clinical trials. Dyspnea resulting from Ticagrelor is self-limiting. Severe Hepatic Impairment: Likely increase in exposure to ticagrelor.
Store below 30°C temperature. Keep away from light and wet place. Keep out of reach of children.